Cargando…
Potential biomarker for diagnosis and therapy of sepsis: Lactylation
INTRODUCTION: As a disease that has plagued human health for decades, sepsis has so far had no specific diagnostic or therapeutic indicators. The discovery of lactylation modifications not only uncovered the deep‐rooted causes of changing between lactate level and pathophysiology and immunology of s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571012/ https://www.ncbi.nlm.nih.gov/pubmed/37904710 http://dx.doi.org/10.1002/iid3.1042 |
_version_ | 1785119889753636864 |
---|---|
author | Sun, ZeXian Song, Yu Li, Jie Li, Yize Yu, YongHao Wang, Xin |
author_facet | Sun, ZeXian Song, Yu Li, Jie Li, Yize Yu, YongHao Wang, Xin |
author_sort | Sun, ZeXian |
collection | PubMed |
description | INTRODUCTION: As a disease that has plagued human health for decades, sepsis has so far had no specific diagnostic or therapeutic indicators. The discovery of lactylation modifications not only uncovered the deep‐rooted causes of changing between lactate level and pathophysiology and immunology of sepsis, but also reaffirmed the inevitable link between metabolic reprogramming and epigenetic reprogramming in sepsis. Lactylation modification became a potential marker for diagnosis and guiding the treatment of sepsis. AIM: In this paper, we will summarize the discovery and regulation of lactylation modifications, discuss the study of lactylation modifications in sepsis, and evaluate their possibility and potential as diagnostic and therapeutic indicators of sepsis. CONCLUSION: Lactylation modification is directly regulated by glycolysis and lactate, and inhibition of glycolytic pathway‐related enzymes can regulate the level of lactylation modification, and more importantly, lactylation modification can act on these enzymes to regulate their functions and feedback regulate the level of glycolysis, this finding provides more ideas for clinical treatment of sepsis. We use “epigenetic modification”, “glycolysis”, “lactate”, “lactylaiton” and “sepsis” as keywords and search the relevant literature through Pubmed and Web of science up to 2023. |
format | Online Article Text |
id | pubmed-10571012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105710122023-10-14 Potential biomarker for diagnosis and therapy of sepsis: Lactylation Sun, ZeXian Song, Yu Li, Jie Li, Yize Yu, YongHao Wang, Xin Immun Inflamm Dis Review Articles INTRODUCTION: As a disease that has plagued human health for decades, sepsis has so far had no specific diagnostic or therapeutic indicators. The discovery of lactylation modifications not only uncovered the deep‐rooted causes of changing between lactate level and pathophysiology and immunology of sepsis, but also reaffirmed the inevitable link between metabolic reprogramming and epigenetic reprogramming in sepsis. Lactylation modification became a potential marker for diagnosis and guiding the treatment of sepsis. AIM: In this paper, we will summarize the discovery and regulation of lactylation modifications, discuss the study of lactylation modifications in sepsis, and evaluate their possibility and potential as diagnostic and therapeutic indicators of sepsis. CONCLUSION: Lactylation modification is directly regulated by glycolysis and lactate, and inhibition of glycolytic pathway‐related enzymes can regulate the level of lactylation modification, and more importantly, lactylation modification can act on these enzymes to regulate their functions and feedback regulate the level of glycolysis, this finding provides more ideas for clinical treatment of sepsis. We use “epigenetic modification”, “glycolysis”, “lactate”, “lactylaiton” and “sepsis” as keywords and search the relevant literature through Pubmed and Web of science up to 2023. John Wiley and Sons Inc. 2023-10-13 /pmc/articles/PMC10571012/ /pubmed/37904710 http://dx.doi.org/10.1002/iid3.1042 Text en © 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Articles Sun, ZeXian Song, Yu Li, Jie Li, Yize Yu, YongHao Wang, Xin Potential biomarker for diagnosis and therapy of sepsis: Lactylation |
title | Potential biomarker for diagnosis and therapy of sepsis: Lactylation |
title_full | Potential biomarker for diagnosis and therapy of sepsis: Lactylation |
title_fullStr | Potential biomarker for diagnosis and therapy of sepsis: Lactylation |
title_full_unstemmed | Potential biomarker for diagnosis and therapy of sepsis: Lactylation |
title_short | Potential biomarker for diagnosis and therapy of sepsis: Lactylation |
title_sort | potential biomarker for diagnosis and therapy of sepsis: lactylation |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571012/ https://www.ncbi.nlm.nih.gov/pubmed/37904710 http://dx.doi.org/10.1002/iid3.1042 |
work_keys_str_mv | AT sunzexian potentialbiomarkerfordiagnosisandtherapyofsepsislactylation AT songyu potentialbiomarkerfordiagnosisandtherapyofsepsislactylation AT lijie potentialbiomarkerfordiagnosisandtherapyofsepsislactylation AT liyize potentialbiomarkerfordiagnosisandtherapyofsepsislactylation AT yuyonghao potentialbiomarkerfordiagnosisandtherapyofsepsislactylation AT wangxin potentialbiomarkerfordiagnosisandtherapyofsepsislactylation |